Numerous studies have been conducted to assess the safety and effectiveness of combining immunotherapies such as anti-TIM3 and anti-PD-1, either alone or in combination with chemotherapy, and explored across diverse tumor types, including GC. The gene discussed is HAVCR2; the disease is gastric cancer.